JP2018502068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502068A5 JP2018502068A5 JP2017530141A JP2017530141A JP2018502068A5 JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5 JP 2017530141 A JP2017530141 A JP 2017530141A JP 2017530141 A JP2017530141 A JP 2017530141A JP 2018502068 A5 JP2018502068 A5 JP 2018502068A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fusion protein
- condition
- high affinity
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 14
- 102000037865 fusion proteins Human genes 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010056559 Graft infection Diseases 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089097P | 2014-12-08 | 2014-12-08 | |
| US62/089,097 | 2014-12-08 | ||
| US201562200557P | 2015-08-03 | 2015-08-03 | |
| US62/200,557 | 2015-08-03 | ||
| PCT/US2015/064572 WO2016094456A1 (en) | 2014-12-08 | 2015-12-08 | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Division JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502068A JP2018502068A (ja) | 2018-01-25 |
| JP2018502068A5 true JP2018502068A5 (OSRAM) | 2018-12-13 |
| JP7095992B2 JP7095992B2 (ja) | 2022-07-05 |
Family
ID=56108081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530141A Active JP7095992B2 (ja) | 2014-12-08 | 2015-12-08 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198225A Pending JP2021035994A (ja) | 2014-12-08 | 2020-11-30 | 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12247062B2 (OSRAM) |
| EP (1) | EP3230311B1 (OSRAM) |
| JP (2) | JP7095992B2 (OSRAM) |
| KR (1) | KR102654033B1 (OSRAM) |
| CN (1) | CN107108718B (OSRAM) |
| AU (1) | AU2015360642B2 (OSRAM) |
| CA (1) | CA2968987C (OSRAM) |
| NZ (1) | NZ732073A (OSRAM) |
| RU (1) | RU2725807C2 (OSRAM) |
| SG (1) | SG11201704124YA (OSRAM) |
| WO (1) | WO2016094456A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| KR102654033B1 (ko) | 2014-12-08 | 2024-04-02 | 1글로브 바이오메디칼 씨오., 엘티디. | 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 |
| AU2019275067A1 (en) * | 2018-05-23 | 2020-12-17 | Manysmart Therapeutics, Inc. | Bispecific T cell engager and uses thereof |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| AU2021301788A1 (en) * | 2020-06-30 | 2023-01-19 | Gaia Biomedicine Inc. | Method for stabilizing binding of NK cell and antibody, and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| IL101147A (en) * | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| ES2176574T3 (es) * | 1996-09-03 | 2002-12-01 | Gsf Forschungszentrum Umwelt | Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral. |
| JP2002522511A (ja) * | 1998-08-11 | 2002-07-23 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法 |
| DK1355942T3 (da) * | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| CA2517074A1 (en) * | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co., Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| US20070292416A1 (en) * | 2003-06-02 | 2007-12-20 | Alexion Pharmaceuticals, Inc. | De-Immunized Anti-Cd3 Antibody |
| KR101229731B1 (ko) * | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| AU2005212830B2 (en) * | 2004-02-16 | 2011-06-02 | Amgen Research (Munich) Gmbh | Less immunogenic binding molecules |
| US20080003225A1 (en) | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| EP2124994A2 (en) * | 2007-01-23 | 2009-12-02 | Zymogenetics, Inc. | Soluble fc gamma r1a for reducing inflammation |
| US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| US20120294857A1 (en) * | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
| CN103429261A (zh) * | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
| BR112014014418A2 (pt) * | 2011-12-15 | 2019-09-24 | Nat Res Council Canada | proteínas de fusão fc de receptor igf solúvel e usos das mesmas |
| US20150037334A1 (en) * | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
| KR102654033B1 (ko) | 2014-12-08 | 2024-04-02 | 1글로브 바이오메디칼 씨오., 엘티디. | 가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도 |
-
2015
- 2015-12-08 KR KR1020177018958A patent/KR102654033B1/ko active Active
- 2015-12-08 NZ NZ732073A patent/NZ732073A/en not_active IP Right Cessation
- 2015-12-08 WO PCT/US2015/064572 patent/WO2016094456A1/en not_active Ceased
- 2015-12-08 US US15/532,770 patent/US12247062B2/en active Active
- 2015-12-08 SG SG11201704124YA patent/SG11201704124YA/en unknown
- 2015-12-08 JP JP2017530141A patent/JP7095992B2/ja active Active
- 2015-12-08 RU RU2017124141A patent/RU2725807C2/ru active
- 2015-12-08 CA CA2968987A patent/CA2968987C/en active Active
- 2015-12-08 EP EP15867381.4A patent/EP3230311B1/en active Active
- 2015-12-08 AU AU2015360642A patent/AU2015360642B2/en not_active Ceased
- 2015-12-08 CN CN201580064820.XA patent/CN107108718B/zh active Active
-
2020
- 2020-11-30 JP JP2020198225A patent/JP2021035994A/ja active Pending
-
2022
- 2022-04-12 US US17/719,194 patent/US20220235115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113710707B (zh) | 结合于psma的重链抗体 | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP7303126B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| Getts et al. | Have we overestimated the benefit of human (ized) antibodies? | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2020525032A5 (OSRAM) | ||
| JP2018502068A5 (OSRAM) | ||
| JP2015163068A5 (OSRAM) | ||
| JP2017532952A5 (OSRAM) | ||
| CN116769032A (zh) | 与cd19结合的重链抗体 | |
| JP2016513467A5 (OSRAM) | ||
| JP2018508483A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| JPWO2019175223A5 (OSRAM) | ||
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2013520984A5 (OSRAM) | ||
| RU2013106217A (ru) | Гибридный белок из антитела против мнс и противовирусного цитокина | |
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| WO2022242703A1 (zh) | 抗msln抗体及其应用 | |
| JP2020533965A5 (OSRAM) | ||
| JP2025146842A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| CN108314734A (zh) | 抗pd－1单克隆抗体及其应用 |